By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Millennium Pharmaceuticals, Inc. (South San Francisco, California) 

256 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-244-6800-Main-650-244-6893-Investor Fax: 650-244-9208


SEARCH JOBS




Collaborations

CuraGen Corporation (Acquired by Celldex Therapeutics, Inc.)  Product Discovery and Pharmacogenomics

Sunesis Pharmaceuticals, Inc.  Cancer Therapeutics





Company News
SEC Sues Filmmaker for Insider Trading Ahead of Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM), Sepracor Acquisitions 9/24/2013 8:52:52 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Announces $13 Million Equity Financing 6/13/2011 7:12:36 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study 5/6/2011 9:15:47 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting 5/5/2011 10:22:01 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Submits Two Supplemental NDAs to FDA for VELCADE 4/26/2011 8:52:43 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) and Sunesis Pharmaceuticals, Inc. (SNSS) Announce Collaboration for Kinase Inhibitors in Oncology; Sunesis Receives a $4 Million Payment 4/5/2011 7:08:06 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Becomes First Licensed Customer for BioClinica, Inc.’s New Enterprise Demand Aggregator 3/30/2011 10:16:55 AM
Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Selects OrgPlus to Deliver Accurate Workforce Insight 7/13/2010 3:33:31 PM
Seattle Genetics, Inc. (SGEN) and Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma 2/3/2010 10:14:32 AM
Seattle Genetics, Inc. (SGEN) Announces Antibody-Drug Conjugate Collaboration With Millennium: The Takeda Oncology Company 4/6/2009 7:23:44 AM
12345678910...
//-->